BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zerp SF, Bibi Z, Verbrugge I, Voest EE, Verheij M. Enhancing radiation response by a second-generation TRAIL receptor agonist using a new in vitro organoid model system. Clin Transl Radiat Oncol 2020;24:1-9. [PMID: 32577539 DOI: 10.1016/j.ctro.2020.05.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Brion R, Gantier M, Biteau K, Taurelle J, Brounais-le Royer B, Verrecchia F, Rédini F, Guiho R. TRAIL-Based Therapies Efficacy in Pediatric Bone Tumors Models Is Modulated by TRAIL Non-Apoptotic Pathway Activation via RIPK1 Recruitment. Cancers 2022;14:5627. [DOI: 10.3390/cancers14225627] [Reference Citation Analysis]
2 Huang KC, Chiang S, Chang H, Chen WT, Yang P, Chen T, Liang J, Shiau A, Ke T, Clifford Chao KS. Engineered sTRAIL-armed MSCs overcome STING deficiency to enhance the therapeutic efficacy of radiotherapy for immune checkpoint blockade. Cell Death Dis 2022;13:610. [DOI: 10.1038/s41419-022-05069-0] [Reference Citation Analysis]
3 Verduin M, Hoeben A, De Ruysscher D, Vooijs M. Patient-Derived Cancer Organoids as Predictors of Treatment Response. Front Oncol 2021;11:641980. [PMID: 33816288 DOI: 10.3389/fonc.2021.641980] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 17.0] [Reference Citation Analysis]